Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Monday. The brokerage issued a hold rating on the stock.

A number of other analysts have also weighed in on the stock. HC Wainwright lowered their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a research note on Monday, August 12th. Northland Securities reaffirmed a market perform rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Brookline Capital Management reissued a hold rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk downgraded shares of Oncternal Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus target price of $20.00.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ:ONCT opened at $1.70 on Monday. The firm’s 50 day simple moving average is $5.02 and its 200-day simple moving average is $7.29. Oncternal Therapeutics has a one year low of $1.32 and a one year high of $13.14. The firm has a market cap of $5.03 million, a PE ratio of -0.14 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. During the same period last year, the business posted ($3.00) EPS. Equities research analysts predict that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is currently owned by hedge funds and other institutional investors.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.